+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market 2024-2028

  • PDF Icon

    Report

  • 163 Pages
  • December 2023
  • Region: Global
  • TechNavio
  • ID: 5568222
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is forecasted to grow by USD 2,230 mn during 2023-2028, accelerating at a CAGR of 15.11% during the forecast period. The report on the ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity of CLTA4 inhibitors, growing popularity of combination therapy, and strategic alliances in developing CLTA4 inhibitors.

The CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is segmented as below:

By Type

  • Monotherapy
  • Combination therapy

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the expansion of research indications of CLTA4 as one of the prime reasons driving the CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market growth during the next few years. Also, special drug designations of CLTA4 inhibitors and increasing awareness about cancer will lead to sizable demand in the market.

The report on the CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market covers the following areas:

  • CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market sizing
  • CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market forecast
  • CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market vendors that include AstraZeneca Plc, Bio Techne Corp., BioNTech SE, Bristol Myers Squibb Co., HBM Holdings Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Xencor Inc., Agenus Inc., Akeso Inc., Innovent Biologics Inc., Molecular Templates Inc., TRACON Pharmaceuticals Inc., and XILIO THERAPEUTICS INC.. Also, the CLTA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size
4.1 Global CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market 2018 - 2022 ($ million)
4.2 Type Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
4.3 Distribution Channel Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Type
6.1 Market segments
Exhibit 30: Chart on Type - Market share 2023-2028 (%)
Exhibit 31: Data Table on Type - Market share 2023-2028 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Monotherapy - Market size and forecast 2023-2028
Exhibit 34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibit 35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibit 36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
6.4 Combination therapy - Market size and forecast 2023-2028
Exhibit 38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibit 40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Type
Exhibit 42: Market opportunity by Type ($ million)
Exhibit 43: Data Table on Market opportunity by Type ($ million)
7 Market Segmentation by Distribution Channel
7.1 Market segments
Exhibit 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibit 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
7.2 Comparison by Distribution Channel
Exhibit 46: Chart on Comparison by Distribution Channel
Exhibit 47: Data Table on Comparison by Distribution Channel
7.3 Hospital pharmacies - Market size and forecast 2023-2028
Exhibit 48: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 49: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 50: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 51: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
7.4 Retail pharmacies - Market size and forecast 2023-2028
Exhibit 52: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 53: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 54: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 55: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
7.5 Online pharmacies - Market size and forecast 2023-2028
Exhibit 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibit 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
7.6 Market opportunity by Distribution Channel
Exhibit 60: Market opportunity by Distribution Channel ($ million)
Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 65: Chart on Geographic comparison
Exhibit 66: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 Germany - Market size and forecast 2023-2028
Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.9 Canada - Market size and forecast 2023-2028
Exhibit 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibit 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.10 UK - Market size and forecast 2023-2028
Exhibit 95: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 96: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibit 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 103: Market opportunity By Geographical Landscape ($ million)
Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 105: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 107: Overview on factors of disruption
11.4 Industry risks
Exhibit 108: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 109: Vendors covered
12.2 Market positioning of vendors
Exhibit 110: Matrix on vendor position and classification
12.3 Agenus Inc.
Exhibit 111: Agenus Inc. - Overview
Exhibit 112: Agenus Inc. - Product / Service
Exhibit 113: Agenus Inc. - Key offerings
12.4 Akeso Inc.
Exhibit 114: Akeso Inc. - Overview
Exhibit 115: Akeso Inc. - Product / Service
Exhibit 116: Akeso Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 117: AstraZeneca Plc - Overview
Exhibit 118: AstraZeneca Plc - Product / Service
Exhibit 119: AstraZeneca Plc - Key news
Exhibit 120: AstraZeneca Plc - Key offerings
12.6 Bio Techne Corp.
Exhibit 121: Bio Techne Corp. - Overview
Exhibit 122: Bio Techne Corp. - Business segments
Exhibit 123: Bio Techne Corp. - Key offerings
Exhibit 124: Bio Techne Corp. - Segment focus
12.7 BioNTech SE
Exhibit 125: BioNTech SE - Overview
Exhibit 126: BioNTech SE - Key offerings
12.8 Bristol Myers Squibb Co.
Exhibit 127: Bristol Myers Squibb Co. - Overview
Exhibit 128: Bristol Myers Squibb Co. - Product / Service
Exhibit 129: Bristol Myers Squibb Co. - Key news
Exhibit 130: Bristol Myers Squibb Co. - Key offerings
12.9 HBM Holdings Ltd.
Exhibit 131: HBM Holdings Ltd. - Overview
Exhibit 132: HBM Holdings Ltd. - Product / Service
Exhibit 133: HBM Holdings Ltd. - Key offerings
12.10 Innovent Biologics Inc.
Exhibit 134: Innovent Biologics Inc. - Overview
Exhibit 135: Innovent Biologics Inc. - Product / Service
Exhibit 136: Innovent Biologics Inc. - Key offerings
12.11 Jiangsu Hengrui Pharmaceuticals Co. Ltd.
Exhibit 137: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Exhibit 138: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Exhibit 139: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
12.12 Merck and Co. Inc.
Exhibit 140: Merck and Co. Inc. - Overview
Exhibit 141: Merck and Co. Inc. - Business segments
Exhibit 142: Merck and Co. Inc. - Key news
Exhibit 143: Merck and Co. Inc. - Key offerings
Exhibit 144: Merck and Co. Inc. - Segment focus
12.13 Ono Pharmaceutical Co. Ltd.
Exhibit 145: Ono Pharmaceutical Co. Ltd. - Overview
Exhibit 146: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibit 147: Ono Pharmaceutical Co. Ltd. - Key offerings
12.14 Shanghai Fosun Pharmaceutical Group Co. Ltd.
Exhibit 148: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Overview
Exhibit 149: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Business segments
Exhibit 150: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Key offerings
Exhibit 151: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Segment focus
12.15 TRACON Pharmaceuticals Inc.
Exhibit 152: TRACON Pharmaceuticals Inc. - Overview
Exhibit 153: TRACON Pharmaceuticals Inc. - Product / Service
Exhibit 154: TRACON Pharmaceuticals Inc. - Key offerings
12.16 Xencor Inc.
Exhibit 155: Xencor Inc. - Overview
Exhibit 156: Xencor Inc. - Product / Service
Exhibit 157: Xencor Inc. - Key news
Exhibit 158: Xencor Inc. - Key offerings
12.17 XILIO THERAPEUTICS INC.
Exhibit 159: XILIO THERAPEUTICS INC. - Overview
Exhibit 160: XILIO THERAPEUTICS INC. - Product / Service
Exhibit 161: XILIO THERAPEUTICS INC. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 162: Inclusions checklist
Exhibit 163: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 164: Currency conversion rates for US$
13.4 Research methodology
Exhibit 165: Research methodology
Exhibit 166: Validation techniques employed for market sizing
Exhibit 167: Information sources
13.5 List of abbreviations
Exhibit 168: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits 18: Historic Market Size - Data Table on global ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market 2018 - 2022 ($ million)
Exhibits 19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
Exhibits 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
Exhibits 23: Five forces analysis - Comparison between 2023 and 2028
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits 29: Chart on Market condition - Five forces 2023 and 2028
Exhibits 30: Chart on Type - Market share 2023-2028 (%)
Exhibits 31: Data Table on Type - Market share 2023-2028 (%)
Exhibits 32: Chart on Comparison by Type
Exhibits 33: Data Table on Comparison by Type
Exhibits 34: Chart on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibits 35: Data Table on Monotherapy - Market size and forecast 2023-2028 ($ million)
Exhibits 36: Chart on Monotherapy - Year-over-year growth 2023-2028 (%)
Exhibits 37: Data Table on Monotherapy - Year-over-year growth 2023-2028 (%)
Exhibits 38: Chart on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibits 39: Data Table on Combination therapy - Market size and forecast 2023-2028 ($ million)
Exhibits 40: Chart on Combination therapy - Year-over-year growth 2023-2028 (%)
Exhibits 41: Data Table on Combination therapy - Year-over-year growth 2023-2028 (%)
Exhibits 42: Market opportunity by Type ($ million)
Exhibits 43: Data Table on Market opportunity by Type ($ million)
Exhibits 44: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits 45: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits 46: Chart on Comparison by Distribution Channel
Exhibits 47: Data Table on Comparison by Distribution Channel
Exhibits 48: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 49: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 50: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 51: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 52: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 53: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 54: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 55: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 56: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 57: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
Exhibits 58: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 59: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
Exhibits 60: Market opportunity by Distribution Channel ($ million)
Exhibits 61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits 65: Chart on Geographic comparison
Exhibits 66: Data Table on Geographic comparison
Exhibits 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
Exhibits 69: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibits 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
Exhibits 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
Exhibits 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
Exhibits 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
Exhibits 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
Exhibits 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
Exhibits 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibits 83: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits 85: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibits 86: Data Table on US - Year-over-year growth 2023-2028 (%)
Exhibits 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
Exhibits 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
Exhibits 91: Chart on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 92: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
Exhibits 93: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 94: Data Table on Canada - Year-over-year growth 2023-2028 (%)
Exhibits 95: Chart on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 96: Data Table on UK - Market size and forecast 2023-2028 ($ million)
Exhibits 97: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibits 98: Data Table on UK - Year-over-year growth 2023-2028 (%)
Exhibits 99: Chart on China - Market size and forecast 2023-2028 ($ million)
Exhibits 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
Exhibits 101: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibits 102: Data Table on China - Year-over-year growth 2023-2028 (%)
Exhibits 103: Market opportunity By Geographical Landscape ($ million)
Exhibits 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits 105: Impact of drivers and challenges in 2023 and 2028
Exhibits 106: Overview on Criticality of inputs and Factors of differentiation
Exhibits 107: Overview on factors of disruption
Exhibits 108: Impact of key risks on business
Exhibits 109: Vendors covered
Exhibits 110: Matrix on vendor position and classification
Exhibits 111: Agenus Inc. - Overview
Exhibits 112: Agenus Inc. - Product / Service
Exhibits 113: Agenus Inc. - Key offerings
Exhibits 114: Akeso Inc. - Overview
Exhibits 115: Akeso Inc. - Product / Service
Exhibits 116: Akeso Inc. - Key offerings
Exhibits 117: AstraZeneca Plc - Overview
Exhibits 118: AstraZeneca Plc - Product / Service
Exhibits 119: AstraZeneca Plc - Key news
Exhibits 120: AstraZeneca Plc - Key offerings
Exhibits 121: Bio Techne Corp. - Overview
Exhibits 122: Bio Techne Corp. - Business segments
Exhibits 123: Bio Techne Corp. - Key offerings
Exhibits 124: Bio Techne Corp. - Segment focus
Exhibits 125: BioNTech SE - Overview
Exhibits 126: BioNTech SE - Key offerings
Exhibits 127: Bristol Myers Squibb Co. - Overview
Exhibits 128: Bristol Myers Squibb Co. - Product / Service
Exhibits 129: Bristol Myers Squibb Co. - Key news
Exhibits 130: Bristol Myers Squibb Co. - Key offerings
Exhibits 131: HBM Holdings Ltd. - Overview
Exhibits 132: HBM Holdings Ltd. - Product / Service
Exhibits 133: HBM Holdings Ltd. - Key offerings
Exhibits 134: Innovent Biologics Inc. - Overview
Exhibits 135: Innovent Biologics Inc. - Product / Service
Exhibits 136: Innovent Biologics Inc. - Key offerings
Exhibits 137: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Overview
Exhibits 138: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Product / Service
Exhibits 139: Jiangsu Hengrui Pharmaceuticals Co. Ltd. - Key offerings
Exhibits 140: Merck and Co. Inc. - Overview
Exhibits 141: Merck and Co. Inc. - Business segments
Exhibits 142: Merck and Co. Inc. - Key news
Exhibits 143: Merck and Co. Inc. - Key offerings
Exhibits 144: Merck and Co. Inc. - Segment focus
Exhibits 145: Ono Pharmaceutical Co. Ltd. - Overview
Exhibits 146: Ono Pharmaceutical Co. Ltd. - Product / Service
Exhibits 147: Ono Pharmaceutical Co. Ltd. - Key offerings
Exhibits 148: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Overview
Exhibits 149: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Business segments
Exhibits 150: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Key offerings
Exhibits 151: Shanghai Fosun Pharmaceutical Group Co. Ltd. - Segment focus
Exhibits 152: TRACON Pharmaceuticals Inc. - Overview
Exhibits 153: TRACON Pharmaceuticals Inc. - Product / Service
Exhibits 154: TRACON Pharmaceuticals Inc. - Key offerings
Exhibits 155: Xencor Inc. - Overview
Exhibits 156: Xencor Inc. - Product / Service
Exhibits 157: Xencor Inc. - Key news
Exhibits 158: Xencor Inc. - Key offerings
Exhibits 159: XILIO THERAPEUTICS INC. - Overview
Exhibits 160: XILIO THERAPEUTICS INC. - Product / Service
Exhibits 161: XILIO THERAPEUTICS INC. - Key offerings
Exhibits 162: Inclusions checklist
Exhibits 163: Exclusions checklist
Exhibits 164: Currency conversion rates for US$
Exhibits 165: Research methodology
Exhibits 166: Validation techniques employed for market sizing
Exhibits 167: Information sources
Exhibits 168: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global ctla4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market: AstraZeneca Plc, Bio Techne Corp., BioNTech SE, Bristol Myers Squibb Co., HBM Holdings Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Xencor Inc., Agenus Inc., Akeso Inc., Innovent Biologics Inc., Molecular Templates Inc., TRACON Pharmaceuticals Inc., and XILIO THERAPEUTICS INC..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is expansion of research indications of CLTA4.'

According to the report, one of the major drivers for this market is the high target affinity and specificity of CLTA4 inhibitors.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca Plc
  • Bio Techne Corp.
  • BioNTech SE
  • Bristol Myers Squibb Co.
  • HBM Holdings Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • Merck and Co. Inc.
  • Ono Pharmaceutical Co. Ltd.
  • Shanghai Fosun Pharmaceutical Group Co. Ltd.
  • Xencor Inc.
  • Agenus Inc.
  • Akeso Inc.
  • Innovent Biologics Inc.
  • Molecular Templates Inc.
  • TRACON Pharmaceuticals Inc.
  • XILIO THERAPEUTICS INC.